Show simple item record

dc.contributor.authorMolnari, Jillissa C.
dc.date.accessioned2011-04-19T15:17:24Z
dc.date.available2011-04-19T15:17:24Z
dc.date.issued2011-04-19T15:17:24Z
dc.identifier.urihttp://hdl.handle.net/2092/1554
dc.descriptionMentor: Alan L. Myersen_US
dc.description.abstractHuman carbonyl reductases (CBRs) are a class of phase I drug metabolizing enzymes that metabolize numerous medications. Patients with pharmacogenetic variations in CBRs have suffered adverse clinical consequences when administered drugs that are CBR substrates. Thus there is a pressing need for pre-screening patients for pharmacogenetic variations in CBRs. Phenotyping patients for pharmacogenetic variations in drug metabolizing enzymes classically involves using a probe substrate for the enzyme. To date, a phenotypic probe for any of the CBRs is currently unknown. A novel probe substrate for CBRs may be bupropion, which is reduced to two diastereomers: erythrohydrobupropion (EBUP) and threohydrobupropion (TBUP). Although speculative, bupropion reduction is likely catalyzed by one or more CBRs. Hence, the objective of this study is to identify the carbonyl reductase(s) responsible for bupropion metabolism in human liver cytosol (HLC). The mean rate of formation (±s.d.) of EBUP and TBUP from bupropion in fresh HLC was 2.27(0.82) pmole/mg/min and 17.4(0.35) pmole/mg/min, respectively. This reaction was NADPH dependent and nullified in the presence of heat-inactivated HLC. The formation of EBUP and TBUP were analyzed in the presence of CBR inhibitors: menadione, flufenamic acid, and 4-methylpyrazole. Menadione, a specific inhibitor of the human carbonyl reductase (CR) enzyme, exhibited an IC50 towards bupropion reduction at 27.3 μM (EBUP) and 87.9 μM (TBUP). EBUP and TBUP formation was not inhibited by flufenamic acid or 4-methylpyrazole. To summarize, bupropion is metabolized to TBUP and EBUP in HLC by CR, suggesting that bupropion has promise as a novel probe substrate for identifying pharmacogenetic variations in CR.en_US
dc.description.sponsorshipDrake University, College of Pharmacy & Health Sciencesen_US
dc.language.isoen_USen_US
dc.relation.ispartofseriesDUCURS 2011;33
dc.subjectCarbonyl reductaseen_US
dc.subjectCytosolen_US
dc.subjectLiveren_US
dc.titleCarbonyl Reduction of Bupropion in Human Liver Cytosolen_US
dc.typePresentationen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

  • DUCURS
    Poster sessions and presentation from the Drake University Conference on Undergraduate Research in the Sciences held each April at Olmsted Center on the Drake campus.

Show simple item record